KalVista Pharmaceuticals, Inc.

KALV

KalVista Pharmaceuticals, Inc.

KALV

Insider Sentiment (TTM):

Last Purchase:2025-04-09Last Sale:2026-05-27Shares Purchased (TTM):0Shares Sold (TTM):217,175

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:68,891,970Shares Outstanding:54,583,424Institutional Ownership Pct.:126.21%

Earnings Market Reaction:

Filing Date:2026-05-14Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-09-30	2025-07-31	2025-04-30	2025-01-31	2024-10-31	2024-07-31	2024-04-30	2024-01-31	2023-10-31	2023-07-31	2023-04-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	214	243	124	132	167	42	32	32	23	58	49	56
Available For Sale Securities Debt Securities Curr…	71	66	67	89	86	94	142	179	53	46	74	93
Receivables Net Current	10	6	2	-	-	-	-	-	-	-	-	-
Inventory Net	4	0	-	-	-	-	-	-	-	-	-	-
Prepaid Expense And Other Assets Current	8	8	12	20	7	5	7	7	6	5	8	6
Assets Current	314	325	206	242	267	152	192	226	104	129	150	172
Property Plant And Equipment Net	3	3	2	2	2	2	2	2	2	3	3	3
Operating Lease Right Of Use Asset	9	9	5	6	5	6	6	7	7	7	8	8
Other Assets Noncurrent	2	2	2	2	1	1	1	1	0	0	0	0
Assets	329	340	216	251	276	161	200	235	114	139	160	183
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	8	8	6	5	6	5	11	9	3	5	5	5
Accrued Liabilities Current	34	21	19	27	18	15	10	12	15	12	8	9
Contract With Customer Liability Current	1	12	11	11	-	-	-	-	-	-	-	-
Operating Lease Liability Current	2	1	2	2	1	2	1	1	1	1	1	1
Liabilities Current	61	45	38	45	26	22	22	23	19	18	14	15
Liabilities Noncurrent
Deferred Revenue Noncurrent	21	-	-	-	-	-	-	-	-	-	-	-
Operating Lease Liability Noncurrent	10	9	4	4	4	5	5	6	6	7	7	7
Liabilities Noncurrent	-	-	136	110	105	5	5	6	6	7	7	7
Convertible Debt Noncurrent	139	139	-	-	-	-	-	-	-	-	-	-
Liabilities	349	323	-	-	-	-	-	-	-	-	-	-
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	774	763	760	754	748	689	686	680	517	514	511	507
Retained Earnings Accumulated Deficit	-786	-739	-713	-653	-601	-552	-510	-470	-425	-396	-368	-343
Accumulated Other Comprehensive Income Loss Net Of…	-7	-7	-6	-5	-2	-3	-3	-3	-3	-3	-3	-3
Stockholders Equity	-20	17	41	95	145	149	173	207	89	114	139	161
Liabilities And Stockholders Equity	329	340	216	251	276	161	200	235	114	139	160	183
Accumulated Depreciation Depletion And Amortizatio…	-	-	5	-	-	-	-	-	-	-	-	-
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	100	100	100	100	100	100	100	100	100	100	100	100
Common Stock Shares Issued	51	51	50	50	49	43	43	43	35	34	34	34
Shares Outstanding	51	51	50	50	49	43	43	43	35	34	34	34

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-19.99%	-26.33%	-2.30%	-	-	-	50.87%	41.97%	43.34%	-	-	-
2025	-4.12%	-9.25%	-21.13%	-5.80%	-4.91%	10.77%	-13.98%	8.84%	-5.22%	-14.83%	-13.22%	-20.05%
2024	-11.16%	-26.29%	-24.82%	36.57%	49.05%	40.25%	-15.34%	-7.40%	-10.92%	5.36%	7.12%	-1.28%
2023	-	-	-	-	-	-	-	-	-	5.54%	1.81%	-8.02%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-03-31	2025-09-30	2025-07-31	2025-04-30	2025-01-31	2024-10-31	2024-07-31	2024-04-30	2024-01-31	2023-10-31	2023-07-31	2023-04-30
Liquidity Ratios
Current Ratio	5.17	7.22	5.37	5.35	10.44	6.87	8.55	9.90	5.44	7.25	10.60	11.46
Quick Ratio	4.97	7.02	5.05	4.92	10.18	6.63	8.22	9.60	5.15	6.94	10.07	11.04
Working Capital	253.39M	280.16M	167.52M	196.52M	241.74M	130.10M	169.22M	202.88M	84.98M	110.86M	135.71M	157.29M
Leverage & Debt
Debt to Equity	-17.74	19.00	4.28	1.63	0.90	0.18	0.16	0.14	0.29	0.21	0.15	0.14
Interest Coverage TTM	-13.41	-24.80	-57.58	-	-	-	-	-	-	-	-	-
Debt Ratio	1.06	0.95	0.81	0.62	0.47	0.17	0.14	0.12	0.22	0.18	0.13	0.12
Efficiency & Turnover
Asset Turnover TTM	0.19	0.06	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding TTM	64.53	139.52	492.98	-	-	-	-	-	-	-	-	-
Receivables Turnover TTM	5.66	2.62	0.74	-	-	-	-	-	-	-	-	-
Per Share Metrics
Diluted EPS TTM	-3.45	-3.96	-3.80	-3.69	-3.28	-3.29	-3.07	-3.44	-3.12	-2.91	-2.77	-3.33
Free Cash Flow Per Share TTM	-3.11	-4.97	-5.60	-5.75	-4.93	-3.75	-2.22	-2.43	-2.79	-2.27	-2.31	-2.74
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-332.01%	-1,358.37%	-14,220.83%	-	-	-	-	-	-	-	-	-
Net Profit Margin TTM	-336.67%	-1,412.19%	-14,242.43%	-	-	-	-	-	-	-	-	-
Growth Metrics
Net Income Growth (1Y)	9.14%	39.35%	43.26%	44.85%	59.45%	52.33%	48.95%	36.31%	19.38%	9.46%	6.62%	12.83%
EPS Growth (1Y)	5.25%	20.49%	23.81%	7.32%	5.18%	13.01%	10.87%	3.35%	-2.77%	-22.11%	-23.92%	-0.99%
Calculated Values
Free Cash Flow TTM	-169.49M	-267.61M	-299.84M	-285.29M	-259.76M	-174.66M	-102.78M	-89.27M	-96.86M	-78.57M	-79.53M	-76.46M
Net Debt	-74.37M	-104.47M	-124.96M	-131.62M	-167.29M	-41.58M	-31.85M	-31.79M	-23.06M	-57.67M	-49.41M	-56.24M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-27Sale

Owner: Yea, Christopher

Title: CHIEF DEVELOPMENT OFFICER

Shares: 33,800

Price/Share: $26.78

Value: $905,164.00

Shares Owned: 229,918

Relationship: Officer

Ownership: Direct

2026-05-26Sale

Owner: Sweeny, Nicole

Title: Chief Commercial Officer

Shares: 1,489

Price/Share: $26.78

Value: $39,875.42

Shares Owned: 59,291

Relationship: Officer

Ownership: Direct

2026-05-26Sale

Owner: Audhya, Paul K.

Title: CHIEF MEDICAL OFFICER

Shares: 2,239

Price/Share: $26.78

Value: $59,960.42

Shares Owned: 150,260

Relationship: Officer

Ownership: Direct

2026-05-26Sale

Owner: Yea, Christopher

Title: CHIEF DEVELOPMENT OFFICER

Shares: 1,966

Price/Share: $26.78

Value: $52,649.48

Shares Owned: 229,918

Relationship: Officer

Ownership: Direct

2026-05-22Sale

Owner: Audhya, Paul K.

Title: CHIEF MEDICAL OFFICER

Shares: 2,685

Price/Share: $26.78

Value: $71,904.30

Shares Owned: 147,499

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-27	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	33,800	26.78	$905,164.00	229,918	4
2026-05-26	Sweeny, Nicole	Officer	Chief Commercial Officer	Direct	Sale	1,489	26.78	$39,875.42	59,291	4
2026-05-26	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,239	26.78	$59,960.42	150,260	4
2026-05-26	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	1,966	26.78	$52,649.48	229,918	4
2026-05-22	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,685	26.78	$71,904.30	147,499	4
2026-05-22	Sweeny, Nicole	Officer	Chief Commercial Officer	Direct	Sale	1,861	26.78	$49,837.58	55,780	4
2026-05-22	Piekos, Brian	Officer	Chief Financial Officer	Direct	Sale	1,489	26.78	$39,875.42	21,661	4
2026-05-22	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	10,926	26.78	$292,598.28	479,989	4
2026-05-22	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	2,358	26.78	$63,147.24	228,759	4
2026-05-18	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	1,032	26.76	$27,616.32	143,934	4
2026-05-18	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	1,129	26.76	$30,212.04	467,665	4
2026-05-18	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	1,108	26.76	$29,650.08	227,367	4
2026-05-12	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	3,322	26.71	$88,730.62	466,375	4
2026-04-17	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	9,550	20.22	$193,101.00	462,577	4
2026-04-17	Piekos, Brian	Officer	Chief Financial Officer	Direct	Sale	1,862	20.22	$37,649.64	18,150	4
2026-04-17	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,686	20.22	$54,310.92	142,547	4
2026-04-17	Sweeny, Nicole	Officer	Chief Commercial Officer	Direct	Sale	1,862	20.22	$37,649.64	51,391	4
2026-03-26	Venrock, Healthcare Capit…	TenPercentOwner	-	Indirect	Sale	39,986	18.57	$742,540.02	5,089,354	4
2026-03-09	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	6,693	16.08	$107,623.44	451,815	4
2026-02-23	Sweeny, Nicole	Officer	Chief Commercial Officer	Direct	Sale	3,975	15.57	$61,890.75	47,003	4
2026-02-23	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	5,354	15.57	$83,361.78	138,983	4
2026-02-23	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	4,347	15.57	$67,682.79	226,701	4
2026-02-23	Piekos, Brian	Officer	Chief Financial Officer	Direct	Sale	1,767	15.57	$27,512.19	13,762	4
2026-02-23	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	10,034	15.57	$156,229.38	442,883	4
2026-02-18	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	1,038	15.00	$15,570.00	429,667	4
2026-02-18	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	1,109	15.00	$16,635.00	224,173	4
2026-02-18	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	1,163	15.00	$17,445.00	133,087	4
2026-02-12	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	3,354	15.70	$52,657.80	428,286	4
2025-12-08	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	7,294	16.51	$120,423.94	424,520	4
2025-11-24	Sweeny, Nicole	Officer	Chief Commercial Officer	Direct	Sale	3,813	13.45	$51,284.85	39,728	4
2025-11-24	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	5,296	13.45	$71,231.20	131,831	4
2025-11-24	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	10,940	13.45	$147,143.00	416,189	4
2025-11-24	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	4,331	13.45	$58,251.95	223,508	4
2025-11-24	Piekos, Brian	Officer	Chief Financial Officer	Direct	Sale	4,471	13.45	$60,134.95	10,529	4
2025-11-18	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	4,466	14.48	$64,667.68	403,879	4
2025-11-18	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	3,075	14.48	$44,526.00	125,877	4
2025-11-18	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	2,683	14.48	$38,849.84	133,574	4
2025-11-12	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	3,328	11.55	$38,438.40	398,981	4
2025-09-08	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	7,294	15.84	$115,536.96	395,189	4
2025-08-25	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,336	13.42	$31,349.12	122,505	4
2025-08-25	Sweeny, Nicole	Officer	Chief Commercial Officer	Direct	Sale	1,480	13.42	$19,861.60	32,291	4
2025-08-25	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	1,954	13.42	$26,222.68	132,052	4
2025-08-22	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	2,362	13.22	$31,225.64	130,881	4
2025-08-22	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	10,940	13.22	$144,626.80	386,858	4
2025-08-22	Sweeny, Nicole	Officer	Chief Commercial Officer	Direct	Sale	1,864	13.22	$24,642.08	28,771	4
2025-08-22	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,942	13.22	$38,893.24	119,841	4
2025-08-18	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	2,649	13.19	$34,940.31	129,493	4
2025-08-18	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,939	13.19	$38,765.41	116,533	4
2025-08-18	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	4,409	13.19	$58,154.71	374,548	4
2025-07-09	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	32,979	15.69	$517,440.51	369,595	4
2025-07-09	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	30,250	15.69	$474,622.50	127,939	4
2025-06-09	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	7,169	14.50	$103,950.50	315,074	4
2025-05-23	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,146	11.31	$24,271.26	113,026	4
2025-05-23	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	1,926	11.31	$21,783.06	98,189	4
2025-05-22	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	9,999	11.88	$118,788.12	306,618	4
2025-05-22	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	2,317	11.88	$27,525.96	96,990	4
2025-05-22	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,689	11.88	$31,945.32	110,172	4
2025-05-19	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	3,808	11.84	$45,086.72	293,367	4
2025-05-19	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	2,600	11.84	$30,784.00	95,557	4
2025-05-19	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,776	11.84	$32,867.84	106,611	4
2025-04-09	Venrock, Healthcare Capit…	TenPercentOwner	-	Indirect	Purchase	25,000	9.42	$235,500.00	5,303,985	4
2025-03-07	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	6,669	11.97	$79,827.93	287,811	4
2025-02-24	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,394	10.02	$23,987.88	102,940	4
2025-02-24	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	1,918	10.02	$19,218.36	93,952	4
2025-02-18	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	2,601	9.82	$25,541.82	92,745	4
2025-02-18	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	5,104	9.82	$50,121.28	278,855	4
2025-02-18	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	3,125	9.82	$30,687.50	100,334	4
2025-02-13	Vhcp, Management Eg, Llc,…	TenPercentOwner	-	Indirect	Purchase	61,700	9.33	$575,661.00	5,278,985	4
2025-02-11	Venrock, Healthcare Capit…	TenPercentOwner	-	Indirect	Purchase	26,703	9.18	$245,133.54	5,117,285	4
2025-02-03	Vhcp, Management Iii, Llc…	TenPercentOwner	-	Indirect	Purchase	14,562	9.22	$134,261.64	5,012,796	4
2024-12-09	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	7,627	9.75	$74,363.25	274,596	4
2024-11-26	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	1,963	9.87	$19,374.81	91,142	4
2024-11-26	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,187	9.87	$21,585.69	97,012	4
2024-11-18	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	8,077	9.26	$74,793.02	94,199	4
2024-11-18	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	14,400	9.26	$133,344.00	266,598	4
2024-11-18	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	7,192	9.26	$66,597.92	89,980	4
2024-09-09	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	7,352	12.19	$89,620.88	250,800	4
2024-08-23	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,135	12.40	$26,474.00	83,745	4
2024-08-23	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	1,916	12.40	$23,758.40	85,676	4
2024-08-19	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	7,102	12.01	$85,295.02	84,467	4
2024-08-19	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	14,215	12.01	$170,722.15	242,527	4
2024-08-19	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	7,973	12.01	$95,755.73	80,880	4
2024-06-07	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	7,465	11.53	$86,071.45	224,547	4
2024-05-20	Feener, Edward P.	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	8,088	11.76	$95,114.88	72,858	4
2024-05-20	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	11,610	11.76	$136,533.60	80,074	4
2024-05-20	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	13,175	11.76	$154,938.00	70,325	4
2024-05-20	Palleiko, Benjamin L	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	21,959	11.76	$258,237.84	216,387	4
2024-02-20	Crockett, Thomas Andrew	Director,Officer	CEO	Direct	Sale	24,888	14.11	$351,169.68	211,203	4
2024-02-20	Audhya, Paul K.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	14,295	14.12	$201,845.40	52,886	4
2024-02-20	Feener, Edward P.	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	28,288	14.29	$404,235.52	62,157	4
2024-02-20	Palleiko, Benjamin L	Officer	CFO, CBO	Direct	Sale	22,802	14.11	$321,736.22	187,315	4
2024-02-20	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	12,053	14.11	$170,067.83	72,895	4
2024-02-14	Palleiko, Benjamin L	Officer	CFO, CBO	Direct	Sale	40,855	15.01	$613,233.55	159,088	4
2024-02-14	Feener, Edward P.	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	28,171	15.01	$422,846.71	71,657	4
2024-02-14	Yea, Christopher	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	39,886	15.01	$598,688.86	66,160	4
2024-02-14	Crockett, Thomas Andrew	Director,Officer	CEO	Direct	Sale	58,356	15.01	$875,923.56	181,676	4
2024-02-08	Shah, Nimish P, Venrock H…	TenPercentOwner	-	Indirect	Purchase	29,747	14.70	$437,280.90	4,824,731	4
2024-02-01	Crockett, Thomas Andrew	Director,Officer	CEO	Direct	Sale	10,000	16.49	$164,900.00	117,532	4
2024-01-30	Venrock, Healthcare Capit…	TenPercentOwner	-	Indirect	Purchase	88,099	14.47	$1,274,792.53	4,738,683	4
2024-01-29	Venrock, Healthcare Capit…	TenPercentOwner	-	Indirect	Purchase	80,600	14.22	$1,146,132.00	4,650,584	4
2024-01-24	Vhcp, Management Eg, Llc,…	TenPercentOwner	-	Indirect	Purchase	20,686	12.44	$257,333.84	4,558,780	4
2024-01-19	Vhcp, Co-Investment Holdi…	TenPercentOwner	-	Indirect	Purchase	25,000	12.43	$310,750.00	4,459,651	4
2024-01-16	Koh, Bong Y, Vhcp Managem…	TenPercentOwner	-	Indirect	Purchase	19,599	12.73	$249,495.27	4,316,046	4
2024-01-11	Feener, Edward P.	Officer	Chief Scientific Officer	Direct	Sale	22,679	13.03	$295,507.37	39,828	4
2024-01-10	Venrock, Healthcare Capit…	TenPercentOwner	-	Indirect	Purchase	47,700	12.67	$604,359.00	4,289,800	4
2024-01-09	Feener, Edward P.	Officer	Chief Scientific Officer	Direct	Sale	100	13.00	$1,300.00	62,507	4
2024-01-04	Shah, Nimish P, Vhcp Mana…	TenPercentOwner	-	Indirect	Purchase	41,764	12.11	$505,762.04	4,152,100	4
2023-12-29	Koh, Bong Y, Venrock Heal…	TenPercentOwner	-	Indirect	Purchase	6,013	12.49	$75,102.37	4,092,731	4
2023-12-27	Crockett, Thomas Andrew	Director,Officer	CEO	Direct	Sale	30,000	12.02	$360,600.00	127,532	4
2023-11-20	Feener, Edward P.	Officer	Chief Scientific Officer	Direct	Sale	4,958	8.23	$40,804.34	79,828	4
2023-11-20	Yea, Christopher	Officer	Chief Development Officer	Direct	Sale	7,113	8.23	$58,539.99	46,046	4
2023-11-20	Palleiko, Benjamin L	Officer	President, CFO, CBO & Sec'y	Direct	Sale	13,008	8.23	$107,055.84	112,443	4
2023-11-20	Audhya, Paul K.	Officer	Chief Medical Officer	Direct	Sale	7,985	8.23	$65,716.55	36,568	4
2023-11-20	Crockett, Thomas Andrew	Director,Officer	CEO	Direct	Sale	14,807	8.23	$121,861.61	157,532	4
2023-09-11	Cha, Albert	Director	-	Direct	Sale	18,000	10.50	$189,000.00	0	4
2023-08-18	Feener, Edward P.	Officer	Chief Scientific Officer	Direct	Sale	4,976	10.73	$53,392.48	73,289	4
2023-08-18	Yea, Christopher	Officer	Chief Development Officer	Direct	Sale	7,142	10.73	$76,633.66	41,662	4
2023-08-18	Crockett, Thomas Andrew	Director,Officer	CEO	Direct	Sale	14,876	10.73	$159,619.48	146,756	4
2023-08-18	Palleiko, Benjamin L	Officer	President, CFO, CBO & Sec'y	Direct	Sale	13,067	10.73	$140,208.91	95,254	4
2023-08-18	Audhya, Paul K.	Officer	Chief Medical Officer	Direct	Sale	8,020	10.73	$86,054.60	26,023	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

126.21%

Inst. Shares: 68,891,970

Shares Outstanding: 54,583,424

2025-12-31

121.98%

Inst. Shares: 66,582,713

Shares Outstanding: 54,583,424

2025-09-30

108.69%

Inst. Shares: 58,567,359

Shares Outstanding: 53,883,681

2025-06-30

101.29%

Inst. Shares: 54,189,406

Shares Outstanding: 53,497,128

2025-03-31

107.62%

Inst. Shares: 53,436,271

Shares Outstanding: 49,652,878

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	68,891,970	54,583,424	126.21%
2025-12-31	66,582,713	54,583,424	121.98%
2025-09-30	58,567,359	53,883,681	108.69%
2025-06-30	54,189,406	53,497,128	101.29%
2025-03-31	53,436,271	49,652,878	107.62%
2024-12-31	55,037,325	52,638,888	104.56%
2024-09-30	48,305,578	46,590,154	103.68%
2024-06-30	48,155,822	46,232,977	104.16%
2024-03-31	46,619,060	36,786,575	126.73%
2023-12-31	36,723,494	34,723,379	105.76%
2023-09-30	35,950,689	34,565,955	104.01%
2023-06-30	32,431,516	34,414,226	94.24%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

KalVista Pharmaceuticals, Inc. (KALV) — SEC Financial Statements & Analysis

KalVista Pharmaceuticals, Inc. (KALV) is a pharmaceutical preparations company, incorporated in DE. KalVista Pharmaceuticals, Inc. trades on Nasdaq as: KALV. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), KalVista Pharmaceuticals, Inc. reported a Debt-to-Equity ratio of -17.74x. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: -17.74x

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is KalVista Pharmaceuticals, Inc. in?

KalVista Pharmaceuticals, Inc. (KALV) operates in the Pharmaceutical Preparations industry.

What exchange does KALV trade on?

KalVista Pharmaceuticals, Inc. (KALV) trades on the Nasdaq.

Where is KalVista Pharmaceuticals, Inc. incorporated?

KalVista Pharmaceuticals, Inc. is incorporated in DE.